{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:16:18Z","timestamp":1794442578410,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1245\/s10434-026-19729-4","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:34:47Z","timestamp":1777919687000},"page":"7023-7035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma"],"prefix":"10.1245","volume":"33","author":[{"given":"Yawen","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kever A.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pereyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Podrascanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galen C.","family":"Gist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Santol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel A.","family":"Kankeu Fonkoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rondell P.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin B.","family":"Conboy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne G.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Nicolas","family":"Vauthey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Newhook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hop S. Tran","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Starlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"19729_CR1","doi-asserted-by":"publisher","first-page":"1321683","DOI":"10.3389\/fonc.2024.1321683","volume":"14","author":"SM Ruff","year":"2024","unstructured":"Ruff SM, Pawlik TM. Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies. Front Oncol. 2024;14:1321683. https:\/\/doi.org\/10.3389\/fonc.2024.1321683.","journal-title":"Front Oncol"},{"key":"19729_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73:198\u2013222. https:\/\/doi.org\/10.3322\/caac.21759.","journal-title":"CA Cancer J Clin"},{"key":"19729_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jhep.2019.11.020","volume":"72","author":"V Mazzaferro","year":"2020","unstructured":"Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72:364\u201377. https:\/\/doi.org\/10.1016\/j.jhep.2019.11.020.","journal-title":"J Hepatol"},{"key":"19729_CR4","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1245\/s10434-020-09478-3","volume":"28","author":"O Utuama","year":"2021","unstructured":"Utuama O, Permuth JB, Dagne G, Sanchez-Anguiano A, Alman A, Kumar A, et al. Neoadjuvant chemotherapy for intrahepatic cholangiocarcinoma: a propensity score survival analysis supporting use in patients with high-risk disease. Ann Surg Oncol. 2021;28:1939\u201349. https:\/\/doi.org\/10.1245\/s10434-020-09478-3.","journal-title":"Ann Surg Oncol"},{"key":"19729_CR5","doi-asserted-by":"publisher","first-page":"6725","DOI":"10.1245\/s10434-020-09536-w","volume":"28","author":"MC Mason","year":"2021","unstructured":"Mason MC, Massarweh NN, Tzeng CWD, Chiang YJ, Chun YS, Aloia TA, et al. Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience. Ann Surg Oncol. 2021;28:6725\u201335. https:\/\/doi.org\/10.1245\/s10434-020-09536-w.","journal-title":"Ann Surg Oncol"},{"key":"19729_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s11605-023-05606-y","volume":"27","author":"A Parente","year":"2023","unstructured":"Parente A, Kamarajah SK, Baia M, Tirotta F, Manzia TM, Hilal MA, et al. Neoadjuvant chemotherapy for intrahepatic, perihilar, and distal cholangiocarcinoma: a national population-based comparative cohort study. J Gastrointest Surg. 2023;27:741\u20139. https:\/\/doi.org\/10.1007\/s11605-023-05606-y.","journal-title":"J Gastrointest Surg"},{"key":"19729_CR7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.amjsurg.2021.02.029","volume":"221","author":"TL Sutton","year":"2021","unstructured":"Sutton TL, Billingsley KG, Walker BS, Enestvedt CK, Dewey EN, Orloff SL, et al. Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Am J Surg. 2021;221:1182\u20137. https:\/\/doi.org\/10.1016\/j.amjsurg.2021.02.029.","journal-title":"Am J Surg"},{"key":"19729_CR8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"key":"19729_CR9","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid"},{"key":"19729_CR10","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet"},{"key":"19729_CR11","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5:824\u201330. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0270.","journal-title":"JAMA Oncol"},{"key":"19729_CR12","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","volume":"30","author":"SK Maithel","year":"2023","unstructured":"Maithel SK, Keilson JM, Cao HST, Rupji M, Mahipal A, Lin BS, et al. NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2023;30:6558\u201366. https:\/\/doi.org\/10.1245\/s10434-023-13809-5.","journal-title":"Ann Surg Oncol"},{"key":"19729_CR13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17991-6","author":"Y Dong","year":"2025","unstructured":"Dong Y, Santol J, Podrascanin V, Li Z, Ammann M, Fonkoua LAK, et al. Conversion to resection after neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for borderline resectable CCA: a real-world exploratory analysis. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-17991-6.","journal-title":"Ann Surg Oncol"},{"key":"19729_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","volume":"77","author":"CL Bowlus","year":"2023","unstructured":"Bowlus CL, Arriv\u00e9 L, Bergquist A, Deneau M, Forman L, Ilyas SI, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77:659\u2013702. https:\/\/doi.org\/10.1002\/hep.32771.","journal-title":"Hepatology"},{"key":"19729_CR15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-18046-6","author":"Y Dong","year":"2025","unstructured":"Dong Y, Podrascanin V, Li Z, Santol J, Ammann M, Fonkoua LAK, et al. Real-world single-center experience with neoadjuvant gemcitabine, cisplatin, and durvalumab in borderline resectable cholangiocarcinoma. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-18046-6.","journal-title":"Ann Surg Oncol"},{"key":"19729_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2017.0117","volume":"152","author":"M Raoof","year":"2017","unstructured":"Raoof M, Dumitra S, Ituarte PHG, Melstrom L, Warner SG, Fong Y, et al. Development and validation of a prognostic score for intrahepatic cholangiocarcinoma. JAMA Surg. 2017;152:e170117. https:\/\/doi.org\/10.1001\/jamasurg.2017.0117.","journal-title":"JAMA Surg"},{"key":"19729_CR17","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149:565\u201374. https:\/\/doi.org\/10.1001\/jamasurg.2013.5137.","journal-title":"JAMA Surg"},{"key":"19729_CR18","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jamasurg.2013.5168","volume":"149","author":"O Hyder","year":"2014","unstructured":"Hyder O, Marques H, Pulitano C, Marsh JW, Alexandrescu S, Bauer TW, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg. 2014;149:432\u20138. https:\/\/doi.org\/10.1001\/jamasurg.2013.5168.","journal-title":"JAMA Surg"},{"key":"19729_CR19","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/XCS.0000000000000557","volume":"236","author":"Z Moazzam","year":"2023","unstructured":"Moazzam Z, Alaimo L, Endo Y, Lima HA, Ruzzenente A, Guglielmi A, et al. Combined tumor burden score and carbohydrate antigen 19\u20139 grading system to predict outcomes among patients with intrahepatic cholangiocarcinoma. J Am Coll Surg. 2023;236:804\u201313. https:\/\/doi.org\/10.1097\/XCS.0000000000000557.","journal-title":"J Am Coll Surg"},{"key":"19729_CR20","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17776-x","author":"J Kawashima","year":"2025","unstructured":"Kawashima J, Akabane M, Woldesenbet S, Tsilimigras DI, Endo Y, Sahara K, et al. Oncological resectability criteria for intrahepatic cholangiocarcinoma: a preoperative framework for multidisciplinary management. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-17776-x.","journal-title":"Ann Surg Oncol"},{"key":"19729_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1365-182X(17)30755-4","volume":"2","author":"SM Strasberg","year":"2000","unstructured":"Strasberg SM, Belghiti J, Clavien PA, Gadzijev E, Garden JO, Lau WY, et al. The Brisbane 2000 terminology of liver anatomy and resections. HPB. 2000;2:333\u20139. https:\/\/doi.org\/10.1016\/S1365-182X(17)30755-4.","journal-title":"HPB"},{"key":"19729_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg"},{"key":"19729_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.surg.2010.10.001","volume":"149","author":"NN Rahbari","year":"2011","unstructured":"Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713\u201324. https:\/\/doi.org\/10.1016\/j.surg.2010.10.001.","journal-title":"Surgery"},{"key":"19729_CR24","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamasurg.2020.1973","volume":"155","author":"DI Tsilimigras","year":"2020","unstructured":"Tsilimigras DI, Sahara K, Wu L, Moris D, Bagante F, Guglielmi A, et al. Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg. 2020;155:823\u201331. https:\/\/doi.org\/10.1001\/jamasurg.2020.1973.","journal-title":"JAMA Surg"},{"key":"19729_CR25","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1245\/s10434-019-07353-4","volume":"26","author":"LS Hu","year":"2019","unstructured":"Hu LS, Zhang XF, Weiss M, Popescu I, Marques HP, Aldrighetti L, et al. Recurrence patterns and timing courses following curative-intent resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2019;26:2549\u201357. https:\/\/doi.org\/10.1245\/s10434-019-07353-4.","journal-title":"Ann Surg Oncol"},{"key":"19729_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.776863","volume":"11","author":"Y Bekki","year":"2021","unstructured":"Bekki Y, Von Ahrens D, Takahashi H, Schwartz M, Gunasekaran G. Recurrent intrahepatic cholangiocarcinoma: review. Front Oncol. 2021;11:776863. https:\/\/doi.org\/10.3389\/fonc.2021.776863.","journal-title":"Front Oncol"},{"key":"19729_CR27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11463-x","author":"WJ Choi","year":"2022","unstructured":"Choi WJ, Williams PJ, Claasen MPAW, Ivanics T, Englesakis M, Gallinger S, et al. Systematic review and meta-analysis of prognostic factors for early recurrence in intrahepatic cholangiocarcinoma after curative-intent resection. Ann Surg Oncol. 2022. https:\/\/doi.org\/10.1245\/s10434-022-11463-x.","journal-title":"Ann Surg Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19729-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19729-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19729-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:37:53Z","timestamp":1783345073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19729-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["19729"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19729-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nguyen H. Tran has received funding or has served as consultant (directed to Mayo Clinic Foundation) for AstraZeneca, DAVA oncology, Elevar, Exact Sciences, Exelixis, Genentech, Ipsen, QED\/Helsinn Therapeutics. Dr. Tran\u2019s research is supported by the National Institute of Minority Health and Health Disparity K23 Career Development Grant (K23MD017217-01A1). The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}